Download PDF
CC BY 4.0 · Surg J (N Y) 2020; 06(02): e135-e138
DOI: 10.1055/s-0040-1712537
Original Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Does Mode of Surgical Intervention Based on Oncotype DX Score Influence Disease Recurrence in Early Breast Cancer?

T. M. Aherne
1   Department of Breast Surgery, University Hospital Galway, Galway, Ireland
,
M. R. Boland
1   Department of Breast Surgery, University Hospital Galway, Galway, Ireland
,
D. Catargiu
2   Department of Pathology, University Hospital Galway, Galway, Ireland
,
K. Bashar
3   Royal College of Surgeons in Ireland, Stephens Green, Dublin, Ireland
,
T. P. McVeigh
1   Department of Breast Surgery, University Hospital Galway, Galway, Ireland
,
C. Brodie
2   Department of Pathology, University Hospital Galway, Galway, Ireland
,
K. J. Sweeney
1   Department of Breast Surgery, University Hospital Galway, Galway, Ireland
4   BreastCheck, Western Unit, Galway, Ireland
› Author Affiliations
Further Information

Publication History

28 February 2020

30 March 2020

Publication Date:
19 June 2020 (online)

Also available at
   Permissions and Reprints

Abstract

Introduction Routine utilization of multigene assays to inform operative decision-making in early breast cancer (EBC) treatment is yet to be established. In this pilot study, we sought to establish the potential benefits of surgical intervention in EBC based on recurrence risk quantification using the Oncotype DX (ODX) assay.

Materials and Methods Consecutive ODX tests performed over a 9-year period from October 2007 to May 2016 were evaluated. Oncotype scores were classified into high (≥31), medium (18–30), or low-risk (0–17) groups. The primary outcome was breast cancer recurrence. Subgroup analysis offered assessment of the recurrence effect of mode of surgical intervention for patient groups as defined by the oncotype score.

Results In total 361 patients underwent ODX testing. The mean age and follow-up were 55.25 (± 10.58) years and 38.59 (± 29.1) months, respectively. The majority of patients underwent wide local excision (86.7%) with 8.9 and 4.4% patients having a mastectomy or wide local excision with completion mastectomy, respectively. Fifty-one percent of patients fell into the low risk ODX category with a further 40.2 and 8.5% deemed to be of intermediate and high risk. Five patients (1.38%) had disease recurrence. Comparative analysis of operative groups in each oncotype group revealed no difference in recurrence scores in the low- (p = 0.84) and high-risk groups (p = 0.92) with a statistically significant difference identified in the intermediate risk group (p = 0.002).

Conclusion To date we have been unable to definitively identify a role for ODX in guiding surgical approach in EBC. There is, however, a need for larger studies to examine this hypothesis.

Keywords

Oncotype DX - early breast cancer - recurrence - surgery
 

  • References

  • 1 Fisher B, Costantino J, Redmond C. , et al. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. N Engl J Med 1989; 320 (08) 479-484
    CrossrefPubMedSearch in Google Scholar
  • 2 Fisher B, Jeong JH, Bryant J. , et al; National Surgical Adjuvant Breast and Bowel Project randomised clinical trials. Treatment of lymph-node-negative, oestrogen-receptor-positive breast cancer: long-term findings from National Surgical Adjuvant Breast and Bowel Project randomised clinical trials. Lancet 2004; 364 (9437): 858-868
    CrossrefPubMedSearch in Google Scholar
  • 3 Fisher B, Dignam J, Wolmark N. , et al. Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer. J Natl Cancer Inst 1997; 89 (22) 1673-1682
    CrossrefPubMedSearch in Google Scholar
  • 4 Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005; 365 (9472): 1687-1717
    CrossrefPubMedSearch in Google Scholar
  • 5 Paik S, Tang G, Shak S. , et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 2006; 24 (23) 3726-3734
    CrossrefPubMedSearch in Google Scholar
  • 6 Paik S, Shak S, Tang G. , et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004; 351 (27) 2817-2826
    CrossrefPubMedSearch in Google Scholar
  • 7 Harris LN, Ismaila N, McShane LM. , et al; American Society of Clinical Oncology. Use of biomarkers to guide decisions on adjuvant systemic therapy for women with early-stage invasive breast cancer: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 2016; 34 (10) 1134-1150
    CrossrefPubMedSearch in Google Scholar
  • 8 Darby S, McGale P, Correa C. , et al; Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials. Lancet 2011; 378 (9804): 1707-1716
    CrossrefPubMedSearch in Google Scholar
  • 9 Solin LJ, Gray R, Baehner FL. , et al. A multigene expression assay to predict local recurrence risk for ductal carcinoma in situ of the breast. J Natl Cancer Inst 2013; 105 (10) 701-710
    CrossrefPubMedSearch in Google Scholar
  • 10 Alvarado M, Carter DL, Guenther JM. , et al. The impact of genomic testing on the recommendation for radiation therapy in patients with ductal carcinoma in situ: a prospective clinical utility assessment of the 12-gene DCIS score™ result. J Surg Oncol 2015; 111 (08) 935-940
    CrossrefPubMedSearch in Google Scholar
  • 11 Rakovitch E, Nofech-Mozes S, Hanna W. , et al. A population-based validation study of the DCIS Score predicting recurrence risk in individuals treated by breast-conserving surgery alone. Breast Cancer Res Treat 2015; 152 (02) 389-398
    CrossrefPubMedSearch in Google Scholar
  • 12 von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. ; STROBE Initiative. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet 2007; 370 (9596): 1453-1457
    CrossrefPubMedSearch in Google Scholar
  • 13 Habel LA, Shak S, Jacobs MK. , et al. A population-based study of tumor gene expression and risk of breast cancer death among lymph node-negative patients. Breast Cancer Res 2006; 8 (03) R25
    CrossrefPubMedSearch in Google Scholar
  • 14 McVeigh TP, Hughes LM, Miller N. , et al. The impact of Oncotype DX testing on breast cancer management and chemotherapy prescribing patterns in a tertiary referral centre. Eur J Cancer 2014; 50 (16) 2763-2770
    CrossrefPubMedSearch in Google Scholar
  • 15 Regan MM, Neven P, Giobbie-Hurder A. , et al; BIG 1-98 Collaborative Group; International Breast Cancer Study Group (IBCSG). Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8·1 years median follow-up. Lancet Oncol 2011; 12 (12) 1101-1108
    CrossrefPubMedSearch in Google Scholar
  • 16 Cuzick J, Sestak I, Baum M. , et al; ATAC/LATTE investigators. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. Lancet Oncol 2010; 11 (12) 1135-1141
    CrossrefPubMedSearch in Google Scholar
  • 17 Lowery AJ, Kell MR, Glynn RW, Kerin MJ, Sweeney KJ. Locoregional recurrence after breast cancer surgery: a systematic review by receptor phenotype. Breast Cancer Res Treat 2012; 133 (03) 831-841
    CrossrefPubMedSearch in Google Scholar
  • 18 Wang J, Xie X, Wang X. , et al. Locoregional and distant recurrences after breast conserving therapy in patients with triple-negative breast cancer: a meta-analysis. Surg Oncol 2013; 22 (04) 247-255
    CrossrefPubMedSearch in Google Scholar